Three-in-one test reveals which men with advanced cancer are suitable for treatment with ‘precision’ drug olaparib
Revolutionary three-in-one blood test could change treatment for advanced stages of disease, say scientists.
A study found a blood test could detect which men with advanced prostate cancer would benefit from new drug treatment. Researchers analysed blood samples from nearly 50 men taking part in a trial of a new drug (olaparib) for prostate…
LONDON, June 19 (Reuters) - Scientists have developed a new
Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca’s drug Lynparza into a precision medicine for prostate cancer. Lynparza, which is already approved for ovarian and recently produced good…
Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca's drug Lynparza into a precision medicine for prostate cancer.
A single blood test could identify how prostate cancer patients will respond to PARP inhibitors in as little as 4 to 8 weeks, say researchers.
The test can also quickly detect if prostate cancer is evolving genetically and might be becoming drug-resistant.